Roughly one in six older adults who take prescription drugs also use herbal or dietary supplements, and the overlap is sending thousands of people to emergency rooms each year. Older patients typically manage several chronic conditions at once, making them especially vulnerable to drug interactions that younger adults rarely face. The gap between how supplements are regulated and how aggressively they are marketed leaves patients, and often their doctors, unaware of the risks hiding in a daily pill organizer.
Why supplement–drug conflicts in older adults demand attention now
Aging changes the way the body absorbs and processes chemicals. Kidneys slow down, liver enzymes shift, and the sheer number of prescriptions climbs. Guidance from the National Institute on Aging stresses that older adults face higher risk from medicines precisely because of multiple conditions and polypharmacy, and it explicitly recommends that clinicians know everything a patient takes, including supplements, in order to support safe medicine use. Yet many patients treat supplements as harmless additions that do not need to be mentioned during a doctor visit.
That communication failure has real consequences. An ambulatory-care safety analysis published through the Agency for Healthcare Research and Quality found that 15.4% of patients used at least one herbal or dietary supplement alongside prescription medications. The same analysis flagged potentially serious interactions in a subset of those patients. Because supplement use is often self-directed and unreported, the true rate of dangerous combinations is likely higher than any single study captures.
A practical question follows from these numbers: would a standardized supplement-use review during Medicare annual wellness visits reduce adverse drug events? No large-scale trial has tested that hypothesis head-on. The NIA’s recommendations already call for full disclosure of supplement use, but there is no structured screening protocol embedded in routine Medicare visits. Without a tested intervention that measures outcomes over at least 12 months, the gap between clinical advice and clinical practice will persist.
Emergency visits and regulatory blind spots behind the numbers
The scale of harm is not theoretical. A nationally representative surveillance study covering 2004 through 2013, published in The New England Journal of Medicine by Andrew Geller and colleagues, estimated that approximately 23,000 U.S. emergency department visits occur each year because of dietary supplement adverse events, based on analysis of national ED data. That figure includes hospitalizations tied to cardiovascular symptoms, allergic reactions, and other acute problems. The most recent publicly available update of that surveillance data ends in 2013, so the current burden could be different given the continued growth of the supplement market.
Specific products carry specific dangers. Ginkgo biloba, one of the most popular herbal supplements among older adults, can increase bleeding risk for people taking anticoagulants such as warfarin, according to the National Center for Complementary and Integrative Health. A patient on warfarin who adds ginkgo without telling a physician could face uncontrolled bleeding, a scenario that is preventable with a single conversation. Other herbs, such as St. John’s wort, can alter liver enzyme activity and reduce the effectiveness of common medications, including some antidepressants and blood thinners, further illustrating how a “natural” product can have potent pharmacologic effects.
The regulatory framework compounds the problem. Under the Dietary Supplement Health and Education Act, known as DSHEA, the Food and Drug Administration exercises only post-market oversight of supplements. As the agency explains in its consumer materials on dietary supplement regulation, manufacturers do not need to prove safety or efficacy before selling a product. The FDA can act only after a supplement reaches shelves and evidence of harm or adulteration accumulates.
A peer-reviewed analysis published in JAMA Network Open documented that FDA warnings issued between 2007 and 2016 identified dietary supplements containing unapproved pharmaceutical ingredients, including active drug compounds hidden in weight-loss and sexual-enhancement products. Those hidden ingredients create overdose and interaction hazards that consumers cannot anticipate from reading a label. For an older adult already taking prescription cardiovascular drugs, an undisclosed stimulant or vasodilator in a supplement can tip the balance toward arrhythmia, dangerously low blood pressure, or stroke.
The combination of minimal pre-market review, widespread consumer trust, and incomplete disclosure to doctors creates a system where older adults absorb the most risk with the least protection. Many patients assume that if a product is sold in a pharmacy or big-box store, it has been vetted like a prescription drug. In reality, the legal standard is closer to that applied to foods, and the burden falls on regulators to react after problems surface rather than on manufacturers to prevent them.
Open questions about supplement safety screening for older patients
Several critical gaps remain in the evidence. The 23,000-visit estimate from the NEJM study relies on data that ended more than a decade ago. No comparable national emergency department surveillance dataset has been published since then to update the figure. The supplement industry has grown substantially in the intervening years, and new product categories, including cannabidiol oils and mushroom extracts, have entered the market without rigorous interaction data in older populations.
Ambulatory-care studies that quantify exact interaction rates specifically among adults 65 and older are also scarce. The 15.4% figure from the AHRQ-hosted analysis covers a broad ambulatory population, not exclusively seniors. Older adults take more prescriptions on average, and they are more likely to have reduced kidney and liver function, which means their interaction risk profile differs from that of a 40-year-old on a single medication. Targeted research in the Medicare-age population would sharpen both the risk estimates and the case for intervention.
There is also no direct primary data linking the hundreds of FDA warning letters about adulterated supplements to measured patient outcomes in older adults. Regulators can document that a product contained an undeclared drug ingredient, but connecting that specific product to a bleeding event, a fall, or an arrhythmia in a person over 65 requires detailed clinical investigation that is rarely done outside of case reports. As a result, policymakers must make decisions in a fog of partial information, relying on signals from emergency departments, poison centers, and adverse event reporting systems that were not designed to capture all relevant details about supplement use.
Another unanswered question is how best to integrate supplement screening into routine care without overburdening clinicians. A brief checklist during Medicare annual wellness visits could ask patients to bring all pills, powders, and teas they use, not just prescriptions. Pharmacists could play a larger role in reviewing supplement–drug combinations, especially for patients on anticoagulants, antiplatelet agents, and narrow-therapeutic-index drugs such as digoxin. Yet these ideas remain largely theoretical; they have not been evaluated in randomized or pragmatic trials that track whether such screening actually reduces emergency visits or hospitalizations.
Bridging the gap between guidance and practice
While researchers work to fill these gaps, several pragmatic steps could reduce risk for older adults right now. Clinicians can normalize conversations about supplements by asking open-ended questions-“What vitamins, herbs, or over-the-counter products do you take?”-and documenting the answers in the medication list. Patients and caregivers can prepare for visits by gathering all products in a single bag and bringing them to appointments, allowing a pharmacist or physician to spot obvious conflicts.
Health systems and insurers can support these efforts by embedding prompts about supplement use in electronic health records and Medicare wellness visit templates. Simple flags for high-risk combinations, such as ginkgo plus warfarin or high-dose biotin plus certain lab tests, could alert clinicians in real time. Public health campaigns aimed at older adults might emphasize that “natural” does not mean “risk-free,” and that telling a doctor about supplement use is a safety measure, not an admission of wrongdoing.
Ultimately, the collision between prescription drugs and dietary supplements in older adults reflects a structural mismatch: potent products are sold under a light-touch regulatory regime to a population whose physiology and medication burden make them exquisitely sensitive to harm. Until surveillance catches up with market reality and systematic screening becomes routine, older Americans will continue to navigate this terrain with less protection than they reasonably expect-and less than they need.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
